Posted by Michael Wonder on 16 Feb 2022
U.S. FDA accepts Mirati Therapeutics' new drug application for adagrasib as treatment of previously treated KRAS G12C mutated non-small cell lung cancer
15 February 2022 - Mirati Therapeutics today announced that the U.S. FDA accepted the new drug application for adagrasib for the treatment of patients with non-small cell lung cancer harbouring the KRASG12C mutation who have received at least one prior systemic therapy.
The Prescription Drug User Fee action date for adagrasib is 14 December 2022.
